Notably, patients with HER2-positive BC exhibited prolonged PFS (6.6 months vs 4.1 months) and higher ORR (31.3% vs 19.5%) compared with their HER2-low-expression counterparts, underscoring the superior efficacy of RC48 in patients with HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.